GRI 0803
Alternative Names: GRI-0803Latest Information Update: 30 Jan 2026
At a glance
- Originator GRI Bio
- Class Anti-inflammatories
- Mechanism of Action Natural killer T cell stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Systemic lupus erythematosus
Most Recent Events
- 26 Jan 2026 The U.S. Patent and Trademark Office (USPTO) issues U.S. Patent No. to GRI Bio, providing robust new intellectual property protection for novel compound compositions central to the Company’s platform of immunomodulators
- 31 Mar 2025 GRI Bio has patent protection for GRI 0803 in Japan
- 23 Dec 2024 The European Patent Office grants notice of allowance for patent covering "Oxygenated Amino or Ammonium-Containing Sulfonic Acid, Phosphonic Acid and Carboxylic Acid Derivatives and Their Medical Use"